Literature DB >> 25647033

MiR-204, down-regulated in retinoblastoma, regulates proliferation and invasion of human retinoblastoma cells by targeting CyclinD2 and MMP-9.

XianJin Wu1, Yong Zeng2, ShaoKe Wu2, JiXin Zhong3, YuZhou Wang3, JunFa Xu4.   

Abstract

Aberrant expression of miR-204 had been frequently reported in cancer studies; however, the mechanism of its function in retinoblastoma remained unknown. Here, we reported that miR-204 was frequently downregulated in retinoblastoma tissues and cell lines. Enforced expression of miR-204 inhibited retinoblastoma cells' proliferation and invasion. In vivo study indicated that restoration of miR-204 inhibited tumor growth. CyclinD2 and MMP-9 were identified as potential targets of miR-204. In addition, a reverse correlation between miR-204 and CyclinD2 or MMP-9 expression was noted in retinoblastoma tissues. Taken together, our results identified a crucial tumor suppressive role of miR-204 in the progression of retinoblastoma.
Copyright © 2015. Published by Elsevier B.V.

Entities:  

Keywords:  CyclinD2; MMP-9; Retinoblastoma; miR-204

Mesh:

Substances:

Year:  2015        PMID: 25647033     DOI: 10.1016/j.febslet.2015.01.030

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  28 in total

Review 1.  Epigenetic regulation of human retinoblastoma.

Authors:  Usha Singh; Manzoor Ahmad Malik; Sandeep Goswami; Swati Shukla; Jasbir Kaur
Journal:  Tumour Biol       Date:  2016-09-17

2.  MiR-204 down-regulation elicited perturbation of a gene target signature common to human cholangiocarcinoma and gastric cancer.

Authors:  Valeria Canu; Andrea Sacconi; Laura Lorenzon; Francesca Biagioni; Federica Lo Sardo; Maria Grazia Diodoro; Paola Muti; Alfredo Garofalo; Sabrina Strano; Antonietta D'Errico; Gian Luca Grazi; Mario Cioce; Giovanni Blandino
Journal:  Oncotarget       Date:  2017-05-02

Review 3.  TRPM3_miR-204: a complex locus for eye development and disease.

Authors:  Alan Shiels
Journal:  Hum Genomics       Date:  2020-02-18       Impact factor: 4.639

4.  MicroRNA-204 inhibits cell proliferation in T-cell acute lymphoblastic leukemia by down-regulating SOX4.

Authors:  Jun-Jie Yin; Bo Liang; Xin-Rong Zhan
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

Review 5.  Biomarkers in retinoblastoma.

Authors:  Jie Sun; Hui-Yu Xi; Qing Shao; Qing-Huai Liu
Journal:  Int J Ophthalmol       Date:  2020-02-18       Impact factor: 1.779

6.  Noninvasive urinary miRNA biomarkers for early detection of pancreatic adenocarcinoma.

Authors:  Silvana Debernardi; Nathalie J Massat; Tomasz P Radon; Ajanthah Sangaralingam; Ana Banissi; Darren P Ennis; Thomas Dowe; Claude Chelala; Stephen P Pereira; Hemant M Kocher; Bryan D Young; Giles Bond-Smith; Robert Hutchins; Tatjana Crnogorac-Jurcevic
Journal:  Am J Cancer Res       Date:  2015-10-15       Impact factor: 6.166

7.  LncRNA MALAT1 exerts oncogenic functions in lung adenocarcinoma by targeting miR-204.

Authors:  Jipeng Li; Jianhua Wang; Yin Chen; Shanfeng Li; Mingwei Jin; Huaying Wang; Zhe Chen; Wanjun Yu
Journal:  Am J Cancer Res       Date:  2016-05-01       Impact factor: 6.166

8.  LncRNA SNHG6 promotes G1/S-phase transition in hepatocellular carcinoma by impairing miR-204-5p-mediated inhibition of E2F1.

Authors:  Kai Chen; Yifu Hou; Rui Liao; Youzan Li; Hongji Yang; Jun Gong
Journal:  Oncogene       Date:  2021-04-06       Impact factor: 9.867

9.  Long non-coding RNA PROX1-AS1 knockdown upregulates microRNA-519d-3p to promote chemosensitivity of retinoblastoma cells via targeting SOX2.

Authors:  Yanyan Chen; Boyang Lu; Lei Liu; Xuefeng Pan; Chunying Jiang; Hui Xu
Journal:  Cell Cycle       Date:  2021-09-29       Impact factor: 5.173

10.  Schizophrenia-Associated MIR204 Regulates Noncoding RNAs and Affects Neurotransmitter and Ion Channel Gene Sets.

Authors:  Sophia Cammaerts; Mojca Strazisar; Bart Smets; Sarah Weckhuysen; Annelie Nordin; Peter De Jonghe; Rolf Adolfsson; Peter De Rijk; Jurgen Del Favero
Journal:  PLoS One       Date:  2015-12-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.